4.1(top 10%)
impact factor
1.1K(top 20%)
papers
24.1K(top 10%)
citations
67(top 10%)
h-index
4.2(top 10%)
impact factor
1.3K
all documents
26.8K
doc citations
110(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1An overview of the c-MET signaling pathwayTherapeutic Advances in Medical Oncology2011647
2Pharmacologic resistance in colorectal cancer: a reviewTherapeutic Advances in Medical Oncology2016385
3The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkersTherapeutic Advances in Medical Oncology2014378
4Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based managementTherapeutic Advances in Medical Oncology2010323
5Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncologyTherapeutic Advances in Medical Oncology2018317
6c-MET as a potential therapeutic target and biomarker in cancerTherapeutic Advances in Medical Oncology2011295
7Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanomaTherapeutic Advances in Medical Oncology2015267
8Review: Targeting the Hedgehog pathway in cancerTherapeutic Advances in Medical Oncology2010262
95-fluorouracil and cardiotoxicity: a reviewTherapeutic Advances in Medical Oncology2018255
10Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapyTherapeutic Advances in Medical Oncology2016240
11HER2-positive breast cancer: new therapeutic frontiers and overcoming resistanceTherapeutic Advances in Medical Oncology2019240
12Circulating tumour cells: their utility in cancer management and predicting outcomesTherapeutic Advances in Medical Oncology2010224
13Treatment of uveal melanoma: where are we now?Therapeutic Advances in Medical Oncology2018224
14CDK4/6 inhibition in breast cancer: current practice and future directionsTherapeutic Advances in Medical Oncology2018218
15Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patientsTherapeutic Advances in Medical Oncology2018200
16Nivolumab in NSCLC: latest evidence and clinical potentialTherapeutic Advances in Medical Oncology2015196
17Treatment options in recurrent ovarian cancer: latest evidence and clinical potentialTherapeutic Advances in Medical Oncology2014189
18Radiation effects on antitumor immune responses: current perspectives and challengesTherapeutic Advances in Medical Oncology2018185
19Predictive and prognostic molecular markers for cancer medicineTherapeutic Advances in Medical Oncology2010178
20Bone and brain metastasis in lung cancer: recent advances in therapeutic strategiesTherapeutic Advances in Medical Oncology2014178
21Health-related quality of life and cancer clinical trialsTherapeutic Advances in Medical Oncology2011173
22Cancer-induced muscle wasting: latest findings in prevention and treatmentTherapeutic Advances in Medical Oncology2017154
23Use of cold-atmospheric plasma in oncology: a concise systematic reviewTherapeutic Advances in Medical Oncology2018151
24Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsTherapeutic Advances in Medical Oncology2013149
25An update on treatment options for pancreatic adenocarcinomaTherapeutic Advances in Medical Oncology2019144
26Nivolumab in melanoma: latest evidence and clinical potentialTherapeutic Advances in Medical Oncology2015124
27Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapiesTherapeutic Advances in Medical Oncology2015123
28PD-L1 expression testing in non-small cell lung cancerTherapeutic Advances in Medical Oncology2018120
29Overcoming docetaxel resistance in prostate cancer: a perspective reviewTherapeutic Advances in Medical Oncology2012114
30Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implicationsTherapeutic Advances in Medical Oncology2017110
31Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trialsTherapeutic Advances in Medical Oncology2019107
32Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variablesTherapeutic Advances in Medical Oncology2011106
33ALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsTherapeutic Advances in Medical Oncology2016106
34MEK and PI3K inhibition in solid tumors: rationale and evidence to dateTherapeutic Advances in Medical Oncology2015105
35Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategiesTherapeutic Advances in Medical Oncology2018105
36Optimal management of hormone receptor positive metastatic breast cancer in 2016Therapeutic Advances in Medical Oncology2015104
37Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancerTherapeutic Advances in Medical Oncology2018104
38The role of the c-Met pathway in lung cancer and the potential for targeted therapyTherapeutic Advances in Medical Oncology2011103
39Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?Therapeutic Advances in Medical Oncology2018102
40Clinical assessment of immune-related adverse eventsTherapeutic Advances in Medical Oncology2018101
41Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)Therapeutic Advances in Medical Oncology2018101
42Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategiesTherapeutic Advances in Medical Oncology201897
43Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesTherapeutic Advances in Medical Oncology201196
44BRCA mutation in ovarian cancer: testing, implications and treatment considerationsTherapeutic Advances in Medical Oncology201796
45Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinomaTherapeutic Advances in Medical Oncology202094
46Tumor heterogeneity in the clinic: is it a real problem?Therapeutic Advances in Medical Oncology201493
47Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implicationsTherapeutic Advances in Medical Oncology201693
48Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapyversuslenvatinib alone for advanced hepatocellular carcinomaTherapeutic Advances in Medical Oncology202191
49Balancing the efficacy and toxicity of chemotherapy in colorectal cancerTherapeutic Advances in Medical Oncology201190
50Erlotinib in the treatment of advanced non-small cell lung cancer: an update for cliniciansTherapeutic Advances in Medical Oncology201287